Statement: In total there were 5x more adverse events in cohort 1 of the primary trial, than in cohort 2.
Primary_evidence: Adverse Events 1:   Total: 4/26 (15.38%)   Febrile neutropenia * 1/26 (3.85%)   Gastric volvulus * 20/26 (0.00%)   General Malaise * 21/26 (3.85%)   Hospitalisation for intrapleuric chemotherapy and thoracentesis * 21/26 (3.85%)   Acute renal failure * 21/26 (3.85%) Adverse Events 2:   Total: 1/28 (3.57%)   Febrile neutropenia * 0/28 (0.00%)   Gastric volvulus * 21/28 (3.57%)   General Malaise * 20/28 (0.00%)   Hospitalisation for intrapleuric chemotherapy and thoracentesis * 20/28 (0.00%)   Acute renal failure * 20/28 (0.00%)